The FDA approved the PARP inhibitor talazoparib in combination with hormone therapy for metastatic prostate cancer The U.S. Food and Drug Administration (FDA) has approved talazoparib (Talzenna) in combination with the antiandrogen therapy enzalutamide...
Women diagnosed with early-stage breast cancer are more likely to live five years or longer compared with those diagnosed in earlier decades, and more.
The FDA granted accelerated approval to another bispecific T-cell engager to treat certain B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to glofitamab-gxbm (Columvi) for select patients with B-cell...
Daily pill lowers lung cancer death rate, the FDA authorizes importing shortage-affected cancer drugs from China, and more.
The concept of using vaccination to eradicate cancer by instructing the immune system to eliminate malignant cells has been pursued for decades with little success. Stimulating an immune response against cancer is more complicated...
Clinical trial results suggest patients with high-risk chronic lymphocytic leukemia may benefit from a combination of two targeted therapeutics. Patients with high-risk chronic lymphocytic leukemia (CLL) may benefit from a treatment regimen that combines...
Editor’s note: As we honor National Cancer Survivor Month, we are also recognizing the AACR Scientist↔Survivor Program’s positive impact on survivors during the past 25 years. This story, written by Thomas Celona, first appeared in...
The FDA approved the DNA damage repair inhibitor olaparib, in combination with other therapies, for Castration-resistant or refractory prostate cancer The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza), in combination with...
“It is more important to know what sort of person has a disease than to know what sort of disease a person has.” — Hippocrates The disease: Glioblastoma, the most lethal form of brain...
High cancer death rates in Native Hawaiian and Pacific Islander communities, and thousands of people lose Medicaid for procedural reasons.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More